I just came back from a 15 hour journey to visit a German dry eye expert for the second time. He said that he is one of those who are conducting the European Phase III trials for Novagali, a novel cationic emulsion formulation of cyclosporine.
He said that the results so far have been very good and despite the fact that the study is double-blind, he can tell from looking at the corneas which patient gets Novagali and which gets the placebo.
This is encouraging.
He said that the results so far have been very good and despite the fact that the study is double-blind, he can tell from looking at the corneas which patient gets Novagali and which gets the placebo.
This is encouraging.
Comment